
|Articles|October 1, 2003
GALDERMA ACHIEVES FDA APPROVAL
Galderma Laboratories has received FDA approval for Clobex (clobetasol propionate 0.05 percent) in a lotion formulation. The class I steroid prescription lotion is designed to control and treat steroid-responsive dermatoses, including moderate-to-severe psoriasis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















